Myasthenia gravis (MG) is a rare autoimmune disorder. B cells produce antibodies against structures located at the junction between nerves and muscles. As a result, affected individuals suffer from muscle weakness and rapid fatigue. B cells are a promising target for modern therapeutic approaches. However, disease-causing B cells are quite rare, which is why it is crucial to gain a better understanding of B cells and their development in the context of MG. In this project, the scientists aim to shed light on the survival system of B cells - the so-called BAFF/APRIL system - which is currently being investigated as part of new MG therapies. The team hopes that this will lead to a deeper understanding of disease progression and the discovery of new biomarkers.

Here you can find further information.